Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DXL1218
- Development stage
- Unknown
- Lead developer
- Daxinlian Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DXL1218 is a humanized monoclonal antibody designed to target CD47, a cell surface glycoprotein that functions as a "don't eat me" signal to the immune system. By binding to CD47, DXL1218 prevents its interaction with Signal Regulatory Protein Alpha (SIRPα) on the surface of macrophages, thereby promoting the phagocytosis of malignant cells. Developed by Daxinlian Biopharmaceutical, the agent is currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors and lymphomas. A key design feature of DXL1218 is its potential to reduce the risk of hemagglutination and treatment-induced anemia, which are frequent dose-limiting toxicities for other CD47-targeting therapies.
- Other names
- anti-CD47 monoclonal antibody DXL1218anti-CD-47 monoclonal antibody DXL1218anti-CD 47 monoclonal antibody DXL1218
02
Targets
CD47 (Cluster of Differentiation 47)
Beyond the preview
Go deeper on DXL1218.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DXL1218.